Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 368

Results For "RI"

11063 News Found

Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections
Drug Approval | June 01, 2026

Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance


Dr. Morepen partners with VIT Bhopal to launch integrated on-campus health centre
Healthcare | June 01, 2026

Dr. Morepen partners with VIT Bhopal to launch integrated on-campus health centre

The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide


MediElaj raises $100K to set up AI-powered healthcare kiosks in underserved regions
Medical Device | June 01, 2026

MediElaj raises $100K to set up AI-powered healthcare kiosks in underserved regions

The company is building a connected healthcare ecosystem that utilises smart healthcare kiosk and mobile app to deliver at-home, AI-assisted health screenings and non-invasive health measurements


Pfizer and FITT IIT Delhi identify 20 health startups under innovation programme
R&D | June 01, 2026

Pfizer and FITT IIT Delhi identify 20 health startups under innovation programme

Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations


AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
Clinical Trials | May 31, 2026

AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,


FDA delays AstraZeneca decision on camizestrant as regulators seek more data
Drug Approval | May 30, 2026

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial


FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
R&D | May 30, 2026

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term